Site Map
PATIENTS
PATIENTS SJIA - PATIENTSHow ACTEMRA Works
Is Actemra Right For You
Patient Stories
Clinical Trials
Taking ACTEMRA
What To Expect
ACTEMRA Dosing
Assessing Response to Treatment
Talking to Your Rheumatologist
Understanding Your Test Results
Setting Goals for Treatment
Your RA Team
RA Profiler
Talking About RA
Information for Caregivers
Paying for ACTEMRA
Appointment Calendar
Recipes
Exercises
Polls
Resources
SJIA - PATIENTS
What to Expect
How ACTEMRA Works
How ACTEMRA is Given
Preparing for Treatment
Diagnosing SJIA
Treating SJIA
Glossary
Paying for ACTEMRA
HEALTHCARE PROFESSIONALS
HEALTHCARE PROFESSIONALS SJIA - HEALTHCARE PROFESSIONALSPatient Types
Clinical Response
ACTEMRA Monotherapy
Safety Profile
ACTEMRA Monitoring
Video Library
Pharmacodynamics
Dosing Calculator
Coverage & Payment
SJIA - HEALTHCARE PROFESSIONALS
ACR Response
Articular Improvements
Systemic Improvements
Steroid Use Reduction
Laboratory Tests
Dosing Calculator
Coverage & Payment
ACTEMRA is indicated for the treatment of adult patients with moderately to severely active rheumatoid arthritis (RA) who have had an inadequate response to one or more tumor necrosis factor (TNF) antagonist therapies.
IMPORTANT SAFETY INFORMATION
Patients treated with ACTEMRA are at increased risk for developing serious infections that may lead to hospitalization or death, including tuberculosis (TB), bacterial, invasive fungal, viral, or other opportunistic infections. If a serious infection develops, interrupt ACTEMRA until the infection is controlled.
ACTEMRA should not be administered to patients with known hypersensitivity to ACTEMRA.
- If anaphylaxis or other clinically significant hypersensitivity reaction occurs, administration of ACTEMRA should be stopped immediately and ACTEMRA should be permanently discontinued.
Other serious or potentially life-threatening adverse reactions that have been reported in clinical trials with ACTEMRA include gastrointestinal perforations and hypersensitivity reactions. Other potential risks of ACTEMRA include demyelinating disorders and malignancies.
Common adverse reactions include upper respiratory infection, nasopharyngitis, headache, hypertension, and increased ALT.
Please see full Prescribing Information, including Boxed Warning for additional important safety information.
The resource above is provided in Adobe® Reader® format (PDF). To view or print, you must have Adobe Reader (version 3.0 or higher) installed on your computer. Download the free Adobe Reader here.
INDICATION
ACTEMRA is indicated for the treatment of adult patients with moderately to severely active rheumatoid arthritis (RA) who have had an inadequate response to one or more tumor necrosis factor (TNF) antagonist therapies.
IMPORTANT SAFETY INFORMATION
Patients treated with ACTEMRA are at increased risk for developing serious infections that may lead to hospitalization or death, including tuberculosis (TB), bacterial, invasive fungal, viral, or other opportunistic infections. If a serious infection develops, interrupt ACTEMRA until the infection is controlled.
ACTEMRA should not be administered to patients with known hypersensitivity to ACTEMRA.
- If anaphylaxis or other clinically significant hypersensitivity reaction occurs, administration of ACTEMRA should be stopped immediately and ACTEMRA should be permanently discontinued.
Other serious or potentially life-threatening adverse reactions that have been reported in clinical trials with ACTEMRA include gastrointestinal perforations and hypersensitivity reactions. Other potential risks of ACTEMRA include demyelinating disorders, malignancies, and changes to certain lab parameters.
Common adverse reactions include upper respiratory infection, nasopharyngitis, headache, hypertension, and increased ALT.
Please see full Prescribing Information including Boxed Warning for additional important safety information.
The resource above is provided in Adobe® Reader® format (PDF). To view or print, you must have Adobe Reader (version 3.0 or higher) installed on your computer. Download the free Adobe Reader here.
